{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T04:16:38Z","timestamp":1787026598966,"version":"build-2736575974"},"reference-count":21,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2022,5,26]],"date-time":"2022-05-26T00:00:00Z","timestamp":1653523200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:p>Thrombotic microangiopathy (TMA) is characterized by microangiopathic hemolytic anemia, thrombocytopenia and organ injury occurring due to endothelial cell damage and microthrombi formation in small vessels. TMA is primary when a genetic or acquired defect is identified, as in atypical hemolytic uremic syndrome (aHUS) or secondary when occurring in the context of another disease process such as infection, autoimmune disease, malignancy or drugs. Differentiating between a primary complement-mediated process and one triggered by secondary factors is critical to initiate timely treatment but can be challenging for clinicians, especially after a kidney transplant due to presence of multiple confounding factors. Similarly, primary membranous nephropathy is an immune-mediated glomerular disease associated with circulating autoantibodies (directed against the M-type phospholipase A2 receptor (PLA2R) in 70% cases) while secondary membranous nephropathy is associated with infections, drugs, cancer, or other autoimmune diseases. Complement activation has also been proposed as a possible mechanism in the etiopathogenesis of primary membranous nephropathy; however, despite complement being a potentially common link, aHUS and primary membranous nephropathy have not been reported together. Herein we describe a case of aHUS due to a pathogenic mutation in complement factor I that developed after a kidney transplant in a patient with an underlying diagnosis of PLA2R antibody associated-membranous nephropathy. We highlight how a systematic and comprehensive analysis helped to define the etiology of aHUS, establish mechanism of disease, and facilitated timely treatment with eculizumab that led to recovery of his kidney function. Nonetheless, ongoing anti-complement therapy did not prevent recurrence of membranous nephropathy in the allograft. To our knowledge, this is the first report of a patient with primary membranous nephropathy and aHUS after a kidney transplant.<\/jats:p>","DOI":"10.3389\/fimmu.2022.909503","type":"journal-article","created":{"date-parts":[[2022,6,3]],"date-time":"2022-06-03T07:30:28Z","timestamp":1654241428000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":16,"title":["Post-Transplant Thrombotic Microangiopathy due to a Pathogenic Mutation in Complement Factor I in a Patient With Membranous Nephropathy: Case Report and Review of Literature"],"prefix":"10.3389","volume":"13","author":[{"given":"Maryam","family":"Saleem","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sana","family":"Shaikh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zheng","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicola","family":"Pozzi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anuja","family":"Java","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2022,5,26]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"589","DOI":"10.1056\/NEJMra020528","article-title":"Thrombotic Microangiopathies","volume":"347","author":"Moake","year":"2002","journal-title":"N Engl J Med"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra1312353","article-title":"Syndromes of Thrombotic Microangiopathy","volume":"371","author":"George","year":"2014","journal-title":"N Engl J Med"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1146\/annurev-med-072211-110606","article-title":"Defective Complement Inhibitory Function Predisposes to Renal Disease","volume":"64","author":"Java","year":"2013","journal-title":"Annu Rev Med"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajkd.2003.07.008","article-title":"Thrombotic Microangiopathy After Renal Transplantation in the United States","volume":"42","author":"Reynolds","year":"2003","journal-title":"Am J Kidney Dis"},{"key":"B5","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1016\/j.trre.2017.10.001","article-title":"De Novo Thrombotic Microangiopathy After Kidney Transplantation","volume":"32","author":"Garg","year":"2018","journal-title":"Transplant Rev"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2019.01326","article-title":"Membranous Nephropathy (MN) Recurrence After Renal Transplantation","volume":"10","author":"Passerini","year":"2019","journal-title":"Front Immunol"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1016\/j.ekir.2020.02.1033","article-title":"Complement Pathways in Membranous Nephropathy: Complex and Multifactorial","volume":"5","author":"Brglez","year":"2020","journal-title":"Kidney Int Rep"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1681\/ASN.2021111488","article-title":"Hematopoietic Stem Cell Transplant-Membranous Nephropathy is Associated With Protocadherin Fat1","volume":"33","author":"Sethi","year":"2022","journal-title":"J Am Soc Nephrol"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1016\/j.ekir.2019.04.003","article-title":"A Multimodality Approach to Assessing Factor I Genetic Variants in Atypical Hemolytic Uremic Syndrome","volume":"4","author":"Java","year":"2019","journal-title":"Kidney Int Rep"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1002\/eji.200838702","article-title":"Genetic, Molecular and Functional Analyses of Complement Factor I Deficiency","volume":"39","author":"Nilsson","year":"2009","journal-title":"Eur J Immunol"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.15252\/embj.201593673","article-title":"Regulators of Complement Activity Mediate Inhibitory Mechanisms Through a Common C3b-Binding Mode","volume":"35","author":"Forneris","year":"2016","journal-title":"EMBO J"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1111\/jth.13571","article-title":"Consensus on the Standardization of Terminology in Thrombotic Thrombocytopenic Purpura and Related Thrombotic Microangiopathies","volume":"15","author":"Scully","year":"2017","journal-title":"J Thromb Haemost"},{"key":"B13","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1016\/j.ekir.2020.10.009","article-title":"Complement in Secondary Thrombotic Microangiopathy","volume":"6","author":"Palma","year":"2021","journal-title":"Kidney Int Rep"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1038\/ki.1989.81","article-title":"Heymann Nephritis: Mechanisms of Renal Injury","volume":"35","author":"Salant","year":"1989","journal-title":"Kidney Int"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2018.01433","article-title":"Alternative Pathway Is Essential for Glomerular Complement Activation and Proteinuria in a Mouse Model of Membranous Nephropathy","volume":"9","author":"Luo","year":"2018","journal-title":"Front Immunol"},{"key":"B16","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1186\/s12882-019-1509-5","article-title":"Complement Activation Products in the Circulation and Urine of Primary Membranous Nephropathy","volume":"20","author":"Zhang","year":"2019","journal-title":"BMC Nephrol"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1016\/j.ekir.2020.02.1033","article-title":"Complement Pathways in Membranous Nephropathy: Complex and Multifactorial","volume":"5","author":"Brglez","year":"2020","journal-title":"Kidney Int Rep"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1016\/j.semnephrol.2013.08.004","article-title":"The Role of Complement in Membranous Nephropathy","volume":"33","author":"Ma","year":"2013","journal-title":"Semin Nephrol"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1681\/ASN.2005010096","article-title":"Contrasting Roles of Complement Activation and its Regulation in Membranous Nephropathy","volume":"16","author":"Cunningham","year":"2005","journal-title":"J Am Soc Nephrol"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1016\/j.ekir.2020.11.032","article-title":"Establishing a Case for Anti-Complement Therapy in Membranous Nephropathy","volume":"6","author":"Ayoub","year":"2020","journal-title":"Kidney Int Rep"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMc1805857","article-title":"Factor H Autoantibodies and Membranous Nephropathy","volume":"379","author":"Seikrit","year":"2018","journal-title":"N Engl J Med"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2022.909503\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,6,3]],"date-time":"2022-06-03T07:30:30Z","timestamp":1654241430000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2022.909503\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,5,26]]},"references-count":21,"alternative-id":["10.3389\/fimmu.2022.909503"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2022.909503","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,5,26]]},"article-number":"909503"}}